Orient Pharma CoROCO:4166 +5.02%56 PB Ratio is 2.58 as of Jul. 07, 2026, which is at its 10-year median of 2.58. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Orient Pharma Co ranks worse than 61.26% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-07), Orient Pharma Co's share price is NT$27.20. Orient Pharma Co's Book Value per Share for the quarter that ended in Dec. 2025 was NT$10.55. Hence, Orient Pharma Co's PB Ratio of today is 2.58.
Good Sign:
Orient Pharma Co Ltd stock PB Ratio (=2.41) is close to 3-year low of 2.24.
The historical rank and industry rank for Orient Pharma Co's PB Ratio or its related term are showing as below:
ROCO:4166'
s PB Ratio Range Over the Past 10 Years
Min: 1.74 Med: 2.58 Max: 4.75
Current: 2.58
During the past 13 years, Orient Pharma Co's highest PB Ratio was 4.75. The lowest was 1.74. And the median was 2.58.
ROCO:4166's PB Ratio is ranked worse than 61.26% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs ROCO:4166: 2.58
During the past 12 months, Orient Pharma Co's average Book Value Per Share Growth Rate was 31.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 21.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 2.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Orient Pharma Co was 21.90% per year. The lowest was -16.10% per year. And the median was -2.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Orient Pharma Co PB Ratio Related Terms
Orient Pharma Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Orient Pharma Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orient Pharma Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Orient Pharma Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Orient Pharma Co (ROCO:4166) has a PB Ratio of 2.58 as of Jul. 07, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orient Pharma Co and its competitors. This is near median its historical median of 2.58. Over the past decade, Orient Pharma Co's PB Ratio has ranged from 1.74 to 4.75. According to the industry distribution chart, Orient Pharma Co ranks #563 out of 919 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is Orient Pharma Co's PB Ratio too high?
Orient Pharma Co's current PB Ratio of 2.58 is near median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 1.74 to a high of 4.75. The Drug Manufacturers industry median PB Ratio is 1.90. Orient Pharma Co's value of 2.58 is 35.8% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #563 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #563 out of 919 companies for PB Ratio. This places Orient Pharma Co in the lower half of its industry. The industry median PB Ratio is 1.90. Orient Pharma Co's value of 2.58 is 35.8% above this benchmark. Historically, Orient Pharma Co's own PB Ratio has ranged from 1.74 to 4.75 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 1.90, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current PB Ratio of 2.58 is 35.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current PB Ratio is 2.58, which is near median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current PB Ratio is 2.58, which is near median its 10-year median of 2.58 and 35.8% above the Drug Manufacturers industry median of 1.90. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current PB Ratio is 2.58 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?
Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued.
The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09.
GuruFocus considers Orient Pharma Co to be Significantly Undervalued.
Key valuation signals for ROCO:4166:
PB Ratio: 2.58 (near median its 10-year median of 2.58)
GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
Industry Position: 35.8% above the Drug Manufacturers median (#563 of 919)
No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score
Get the complete analysis for ROCO:4166
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4166 has been successfully added to your 
